A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2015; you can also visit the original URL.
The file type is application/pdf
.
Safety of low-dose spironolactone administration in chronic haemodialysis patients
2003
Nephrology, Dialysis and Transplantation
Background. Prevention of cardiovascular diseases is essential in chronic haemodialysis patients. Recently, low-dose spironolactone has been shown to decrease cardiovascular mortality in patients with severe heart failure. However, since haemodialysis patients are prone to hyperkalaemia, a known side effect of spironolactone, this treatment is not used in this population. We performed a study to assess whether low-dose spironolactone (3 Â 25 mg/week) could be administered without inducing
doi:10.1093/ndt/gfg388
pmid:14551366
fatcat:d53kpw5hrzdktnvchurzonvaxe